Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.37 USD | +0.06% | -1.77% | +31.07% |
Financials (USD)
Sales 2024 * | 52.9M | Sales 2025 * | 67.47M | Capitalization | 2.05B |
---|---|---|---|---|---|
Net income 2024 * | -218M | Net income 2025 * | -252M | EV / Sales 2024 * | 28.9 x |
Net cash position 2024 * | 516M | Net cash position 2025 * | 463M | EV / Sales 2025 * | 23.5 x |
P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
-9.47
x | Employees | 187 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.62% |
Latest transcript on Kymera Therapeutics, Inc.
1 day | +0.06% | ||
1 week | -1.77% | ||
Current month | -16.99% | ||
1 month | -15.50% | ||
3 months | +7.58% | ||
6 months | +189.92% | ||
Current year | +31.07% |
Managers | Title | Age | Since |
---|---|---|---|
Nello Mainolfi
FOU | Founder | 45 | 15-08-31 |
Bruce Jacobs
DFI | Director of Finance/CFO | 54 | 19-07-14 |
Juliet Williams
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | Mar. 27 |
Joanna Horobin
BRD | Director/Board Member | 69 | 18-04-30 |
John Maraganore
BRD | Director/Board Member | 60 | 22-01-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.09% | 0 M€ | 0.00% | - | |
0.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 33.37 | +0.06% | 452,011 |
24-04-25 | 33.35 | -5.28% | 786,230 |
24-04-24 | 35.21 | -1.40% | 379,566 |
24-04-23 | 35.71 | +3.96% | 437,029 |
24-04-22 | 34.35 | +1.12% | 417,209 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.07% | 2.05B | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- KYMR Stock